Vident Advisory, LLC

Position in ALNY — Alnylam Pharmaceuticals, Inc.

CIK 1744347 Alpharetta, GA

Position in ALNY

as of Mar 31, 2026 · filed May 15, 2026 Compact

Position Value

$2,136,426

+$86,541 QoQ

Shares Held

6,457

+25.3% QoQ

Ownership

0.005%

of shares outstanding

% of Portfolio

0.02%

of 13F equity value

Holder Rank

—

not a current holder

Holding Since

Sep 2023

11 quarters on record

Voting authority Sole 98.93139228743999.ToString("F0")% Shared 0.ToString("F0")% None 1.0686077125600124.ToString("F0")%

Healthcare · as of Mar 31, 2026

Vident Advisory, LLC holds $44,934,093 across 44 Biotechnology names. ALNY ranks #5 (4.8% of the industry book) .

#	Ticker	Company	Shares	Value (USD)
1	VRTX	Vertex Pharmaceuticals Inc / Ma	16,063	$7,172,769
2	EXEL	Exelixis, Inc.	148,830	$6,383,317
3	JAZZ	Jazz Pharmaceuticals plc	23,032	$4,354,199
4	REGN	Regeneron Pharmaceuticals, Inc.	3,449	$2,664,834
5	ALNY	Alnylam Pharmaceuticals, Inc. This page	6,457	$2,136,426
6	INSM	INSMED Inc	9,808	$1,603,803
7	GMAB	Genmab A/S	48,379	$1,298,008
8	CYTK	Cytokinetics Inc	17,069	$1,125,017

11 filing rows on record

Report Date	Value (USD)	Shares	Change	Type	Discretion	Filed
2026-03-31	$2,136,426	6,457	+25.3%	Shares	Sole	2026-05-15
2025-12-31	$2,049,885	5,155	-1.6%	Shares	Defined	2026-02-18
2025-09-30	$2,388,072	5,237	+33.4%	Shares	Defined	2025-11-14
2025-06-30	$1,279,902	3,925	+47.2%	Shares	Sole	2025-08-14
2025-03-31	$720,143	2,667	+101.0%	Shares	Defined	2025-05-15
2024-12-31	$312,255	1,327	+21.2%	Shares	Defined	2025-02-14
2024-09-30	$301,157	1,095	-37.4%	Shares	Sole	2024-11-14
2024-06-30	$425,007	1,749	+12.0%	Shares	Sole	2024-08-14
2024-03-31	$233,290	1,561	-16.5%	Shares	Defined	2024-05-14
2023-12-31	$357,744	1,869	+7.1%	Shares	Sole	2024-02-14
2023-09-30	$309,038	1,745	—	Shares	Defined	2024-02-21
No filing history on record for this holder in this stock.